Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma.

[1]  M. Pellegrini,et al.  The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma , 2020, Proceedings of the National Academy of Sciences.

[2]  A. Pastor,et al.  Extracellular Vesicle-Mediated Communication between the Glioblastoma and Its Microenvironment , 2019, Cells.

[3]  M. Mehta,et al.  Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. , 2019, Neuro-oncology.

[4]  S. Khatua,et al.  Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201 , 2019, Journal of Neuro-Oncology.

[5]  S. Libutti,et al.  Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration , 2019, Journal of Immunotherapy for Cancer.

[6]  Andrew B. Leber,et al.  Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. , 2019, Cancer cell.

[7]  F. Azuaje,et al.  Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment , 2019, Nature Communications.

[8]  M. Mehta,et al.  First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. , 2019, Journal of neurosurgery. Pediatrics.

[9]  Bin Zhang,et al.  Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment , 2019, EBioMedicine.

[10]  Michael L. Wang,et al.  Integrated stress response and immune cell infiltration in an ibrutinib‐refractory mantle cell lymphoma patient following ONC201 treatment , 2019, British journal of haematology.

[11]  Atique U. Ahmed,et al.  Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma , 2019, The Journal of Neuroscience.

[12]  Yue-hua Chen,et al.  A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment , 2019, Drug delivery.

[13]  A. Kim,et al.  Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma , 2018, Front. Oncol..

[14]  N. Neamati,et al.  Current Challenges and Opportunities in Treating Glioblastoma , 2018, Pharmacological Reviews.

[15]  U. McDermott,et al.  Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies , 2018, Cell cycle.

[16]  Neel S. Madhukar,et al.  Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors , 2017, PloS one.

[17]  Wei Li,et al.  Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells , 2017, Journal of molecular cell biology.

[18]  P. Wen,et al.  A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma , 2017, Oncotarget.

[19]  R. DiPaola,et al.  First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors , 2017, Clinical Cancer Research.

[20]  C. Gasch,et al.  Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention , 2017, Molecular Cancer.

[21]  Erwin G. Van Meir,et al.  Overcoming therapeutic resistance in glioblastoma: the way forward. , 2017, The Journal of clinical investigation.

[22]  A. Idbaih,et al.  Blood-brain barrier, cytotoxic chemotherapies and glioblastoma , 2016, Expert review of neurotherapeutics.

[23]  J. Lemée,et al.  Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. , 2015, Neuro-oncology.

[24]  Atique U. Ahmed,et al.  The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence , 2015, Expert review of neurotherapeutics.

[25]  J. Rich,et al.  Cancer stem cells in glioblastoma , 2015, Genes & development.

[26]  W. El-Deiry,et al.  Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway , 2015, Molecular Cancer.

[27]  Bernard Rogister,et al.  Glioblastoma-Initiating Cells: Relationship with Neural Stem Cells and the Micro-Environment , 2013, Cancers.

[28]  K. Makino,et al.  Glioma Initiating Cells Form a Differentiation Niche Via the Induction of Extracellular Matrices and Integrin αV , 2013, PloS one.

[29]  Atique U. Ahmed,et al.  Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies , 2013, Expert review of neurotherapeutics.

[30]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[31]  E. Messaris,et al.  Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects , 2013, Science Translational Medicine.

[32]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[33]  Erika Pastrana,et al.  Eyes wide open: a critical review of sphere-formation as an assay for stem cells. , 2011, Cell stem cell.

[34]  S. Lyle,et al.  Quiescent, Slow-Cycling Stem Cell Populations in Cancer: A Review of the Evidence and Discussion of Significance , 2010, Journal of oncology.

[35]  K. Miyazono,et al.  Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. , 2009, Cell stem cell.

[36]  Giuseppe Trapani,et al.  New strategies to deliver anticancer drugs to brain tumors , 2009, Expert opinion on drug delivery.

[37]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[38]  L. Ricci-Vitiani,et al.  Chemotherapy resistance of glioblastoma stem cells , 2006, Cell Death and Differentiation.

[39]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[40]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  N. Laperriere,et al.  Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  Benedick A Fraass,et al.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.